Introduction
Preeclampsia remains a leading cause of maternal and neonatal morbidity and mortality worldwide. While significant progress has been made in the early prediction and prevention of the disease, managing patients once a diagnosis has been established—particularly in early-onset cases—remains a complex clinical challenge. Current strategies focus on first-trimester screening (11–14 weeks) using a combination of maternal characteristics, uterine artery Doppler, and biomarkers like placental growth factor (PlGF). When high-risk patients are identified early and prescribed 150 mg of aspirin, the incidence of preeclampsia before 32 weeks can be reduced by as much as 90%.
However, screening is not universal, and aspirin is not a panacea. For the women who still develop early-onset preeclampsia, clinicians must decide between the risks of prematurity associated with early delivery and the risks of maternal or fetal complications associated with expectant management. This commentary explores recent research by Peguero et al. (BJOG 2020) regarding the use of soluble fms-like tyrosine kinase 1 (sFlt-1) as a longitudinal tool for risk stratification after diagnosis.
From Diagnosis to Prognosis
The sFlt-1:PlGF ratio is already a validated tool for the rule-out of preeclampsia in women with suspected disease. The PROGNOSIS study (Zeisler H et al., 2016) established that a ratio below 38 has a negative predictive value of 99.3% for the need for delivery within the subsequent week. While this is invaluable for reducing unnecessary hospitalizations in suspected cases, its utility after a confirmed diagnosis has been less clear.
Peguero and colleagues shifted the focus from a single "snapshot" measurement to the rate of change in these biomarkers—specifically the "delta sFlt-1." By tracking 63 women with early-onset preeclampsia from diagnosis to delivery, the researchers sought to determine if the trajectory of these biomarkers could predict the interval to delivery and the likelihood of adverse outcomes.
Key Findings: The Power of the "Delta"
The study revealed several critical insights into the biological progression of the disease:
- sFlt-1 Trajectory as a Predictor: Changes in sFlt-1 levels were significantly more pronounced in women who later developed complications. This "delta sFlt-1" was negatively associated with the interval to delivery, meaning a sharper rise in the protein indicated a more rapid disease progression.
- Superiority Over Static Scores: The rate of change in sFlt-1 outperformed both single-point admission measurements and previously published clinical risk scores in predicting maternal and fetal complications.
- The Specificity of sFlt-1: Interestingly, while PlGF is a vital component of early-onset screening, the study found no significant association between the change in PlGF levels and the development of adverse outcomes after diagnosis. The prognostic power appears to be driven primarily by sFlt-1.
Clinical Implications
These findings suggest that serial sFlt-1 measurements could serve as a "biological clock" for clinicians managing early-onset preeclampsia. By identifying women at lower risk of immediate complications, doctors can more confidently pursue expectant management to allow for further fetal development. Conversely, identifying women with a high delta sFlt-1 allows for the timely administration of corticosteroids for fetal lung maturation and the urgent transfer of the mother to tertiary healthcare facilities equipped with advanced neonatal intensive care units.
Limitations and Future Directions
While the results are promising, the Peguero study was limited by a small sample size of 63 women. Larger, multi-center prospective trials are necessary to establish standardized "delta" thresholds for clinical use. Furthermore, there remains a gap between clinical evidence and implementation; while early screening is feasible, real-world physician compliance with aspirin protocols varies significantly (29% in usual care versus 99% in implementation studies).
Conclusion
The shift from using sFlt-1:PlGF as a one-time diagnostic tool to using serial sFlt-1 measurements as a prognostic indicator represents a significant step forward in personalized obstetric care. For cases where prevention fails, longitudinal biomarker monitoring offers a potential roadmap for navigating the delicate balance between maternal safety and neonatal maturity.
Summary updated